These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29581884)

  • 1. The BC Glomerulonephritis Network: Improving Access and Reducing the Cost of Immunosuppressive Treatments for Glomerular Diseases.
    Barbour S; Lo C; Espino-Hernandez G; Gill J; Levin A
    Can J Kidney Health Dis; 2018; 5():2054358118759551. PubMed ID: 29581884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of the British Columbia Glomerulonephritis network and registry: integrating knowledge generation and translation within a single framework.
    Barbour S; Beaulieu M; Gill J; Djurdjev O; Reich H; Levin A
    BMC Nephrol; 2013 Oct; 14():236. PubMed ID: 24168011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.
    Naipaul R; Marques C; Ng J; Barbour S; Lo C; Hildebrand AM; Siu V; Prasad B; Laurin LP; Wazny LD; Armstrong S; Tran J; Sheffield M; Jauhal A; Hladunewich MA
    Can J Kidney Health Dis; 2023; 10():20543581231190227. PubMed ID: 37581108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Provincial Needs Assessment to Determine the Current State of Glomerulonephritis Care in Ontario.
    Pang J; D'Antonio C; Heale E; Boll P; Blake P; Evans JM; Hladunewich M
    Can J Kidney Health Dis; 2019; 6():2054358119877405. PubMed ID: 31565235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice.
    Barbour S; Lo C; Espino-Hernandez G; Sajjadi S; Feehally J; Klarenbach S; Gill J
    Nephrol Dial Transplant; 2018 Apr; 33(4):626-634. PubMed ID: 29106654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure and Function of a Provincial Renal Pharmacy Program: Applying the Chronic Care Model to Address Equitable Access to Medication and Pharmacy Services.
    Roohi E; Lo C; Martinusen D; Levin A
    Can J Kidney Health Dis; 2023; 10():20543581231177840. PubMed ID: 37313363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-specific incident glomerulonephritis displays geographic clustering in under-serviced rural areas of British Columbia, Canada.
    Canney M; Induruwage D; McCandless LC; Reich HN; Barbour SJ
    Kidney Int; 2019 Aug; 96(2):421-428. PubMed ID: 31113679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BC ADPKD Network: A Comprehensive Provincial Approach to Support Specialized and Locally Delivered Multidisciplinary ADPKD Care.
    Bevilacqua M; Gradin S; Williams J; Romann A; Lo C; Djurdjev O; Levin A
    Can J Kidney Health Dis; 2021; 8():20543581211035218. PubMed ID: 34377502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving performance management for delivering appropriate care for patients no longer needing acute hospital care.
    Penney C; Henry E
    J Health Serv Res Policy; 2008 Jan; 13 Suppl 1():30-4. PubMed ID: 18325166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cohort profile: the Comparative Outcomes And Service Utilization Trends (COAST) Study among people living with and without HIV in British Columbia, Canada.
    Eyawo O; Hull MW; Salters K; Samji H; Cescon A; Sereda P; Lima VD; Nosyk B; Whitehurst DGT; Lear SA; Montaner JSG; Hogg RS;
    BMJ Open; 2018 Jan; 8(1):e019115. PubMed ID: 29331972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists.
    Barbour S; Beaulieu M; Gill J; Espino-Hernandez G; Reich HN; Levin A
    Clin Kidney J; 2014 Dec; 7(6):538-45. PubMed ID: 25859369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis.
    Goto Y; Yamaguchi S; Tamura M; Mochizuki H; Kurumatani H; Okano K; Miyamoto M
    Prostaglandins Other Lipid Mediat; 2014 Aug; 112():16-26. PubMed ID: 24992870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Initial Hemodialysis Vascular Access Use Among Glomerulonephritis Subtypes in the United States.
    O'Shaughnessy MM; Montez-Rath ME; Zheng Y; Lafayette RA; Winkelmayer WC
    Am J Kidney Dis; 2016 Apr; 67(4):638-47. PubMed ID: 26774466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular risk is similar in patients with glomerulonephritis compared to other types of chronic kidney disease: a matched cohort study.
    Hutton HL; Levin A; Gill J; Djurdjev O; Tang M; Barbour SJ
    BMC Nephrol; 2017 Mar; 18(1):95. PubMed ID: 28320366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fundamental concepts and immunosuppressive treatment in the various forms of glomerulonephritis.
    Keller F; Schwarz A
    Ren Fail; 1995 Jan; 17(1):1-11. PubMed ID: 7770638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Action Schools! BC implementation: from efficacy to effectiveness to scale-up.
    McKay HA; Macdonald HM; Nettlefold L; Masse LC; Day M; Naylor PJ
    Br J Sports Med; 2015 Feb; 49(4):210-8. PubMed ID: 25312876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and outcomes of paid undergraduate student nurse positions.
    Gamroth L; Budgen C; Lougheed M
    Nurs Leadersh (Tor Ont); 2006 Sep; 19(3):e1-14. PubMed ID: 19830923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of restrictive prescription plans on heart failure medication use.
    Thanassoulis G; Karp I; Humphries K; Tu JV; Eisenberg MJ; Pilote L
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):484-90. PubMed ID: 20031881
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.